Le Lézard
Classified in: Health, Science and technology

Genomenon Awarded NIH NHGRI Grant to Curate the Human Genome


ANN ARBOR, Mich., Feb. 15, 2022 /PRNewswire-PRWeb/ -- Genomenon, Inc., an AI-driven genomics company, today announced that it was awarded a $1.7 million grant by the National Institutes of Health (NIH) through the Small Business Innovation Research (SBIR) program. The grant is to accelerate development of the Mastermind® Genomic Search Engine, the company's AI-driven variant interpretation engine, with a vision of curating the entire human genome. The grant enables Genomenon to increase the expertly curated evidence needed for clinicians to make a genetic diagnosis, extending Mastermind beyond its current function as the most complete source of genomic information for medical research.

The NIH's SBIR program focuses on a variety of high-impact technologies spanning research tools, diagnostics, digital health, drugs, and medical devices. It provides funding needed to bring scientific innovations from bench to bedside. Awarded by the NIH's National Human Genome Research Institute, this grant will fund the continued evolution of Genomenon's AI-driven genomic engine, as well as the incorporation of collaborative features for community-based variant interpretation¹.

"Having already curated more than 250 genes for rare diseases and cancer, this NIH funding allows us to accelerate the pace of genetic interpretation for our AI-driven curation engine, which is a crucial first step in a process that enables targeted and efficient use of expert human curators," said Mike Klein, CEO of Genomenon. "Next-generation sequencing gives us the ability to quickly and efficiently create a large amount of genomic data. Curating the entire genome for meaning and actionability at scale is the next step in the evolution of using this information to improve patient care."

Mastermind is the world's most comprehensive source for genomic literature in the variant interpretation space. Used by more than 1,000 diagnostic labs and integrated into 18 clinical-grade decision support platforms and reference databases across the globe, Mastermind connects patient genetic data with critical evidence from scientific literature needed to diagnose rare genetic diseases and cancer.

About Genomenon

Genomenon is an AI-driven genomics company that organizes the world's genomic knowledge to connect patient DNA to scientific research in the diagnosis and development of treatments for patients with rare genetic diseases and cancer.

For more information, visit Genomenon.com
_________________________________________

1. Research reported in this publication was supported by the National Human Genome Research Institute of the National Institutes of Health under Award Number R43HG010446. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

Media Contact

Candace Chapman, Genomenon, 1-734-219-5175, [email protected]

 

SOURCE Genomenon


These press releases may also interest you

at 16:10
Nuvation Bio Inc. , a late clinical-stage, global biopharmaceutical company tackling some of the greatest unmet needs in oncology by developing differentiated and novel therapeutic candidates, announced today that David Hung, M.D., Founder,...

at 16:10
Vir Biotechnology, Inc. today announced that Marianne De Backer, M.Sc., Ph.D., MBA, Chief Executive Officer is scheduled to participate in a fireside chat at the Goldman Sachs 45th Annual Global Healthcare Conference on Wednesday, June 12, at 11:00...

at 16:10
Allurion Technologies, Inc. , a company dedicated to ending obesity, today announced that it will be participating in two upcoming investor conferences: Jefferies Global Healthcare Conference Sidoti Small Cap Virtual Conference About...

at 16:10
Agilent Technologies Inc. today reported revenue of $1.57 billion for the second quarter ended April 30, 2024, a decline of 8.4% reported and 7.4% core(1) compared to the second quarter of 2023. Second-quarter GAAP net income was $308 million, or...

at 16:05
Kezar Life Sciences, Inc. , a clinical-stage biotechnology company developing novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer, today announced that Chris Kirk, Co-founder and Chief Executive Officer, will...

at 16:05
GlycoMimetics, Inc. a late clinical-stage biotechnology company discovering and developing glycobiology-based therapies for cancers and inflammatory diseases, today announced that it will host a key opinion leader event on Tuesday, June 4, 2024, at...



News published on and distributed by: